Seer, Inc. SEER
Set alert
1.75 USD +0.07 +4.13%
As of Nov 2, 2:20 PM ET
1.65 Day range 1.78
1.55 52-week range 2.38
- YTD
- -4.41%
- 1 year
- -20.85%
- Open
- 1.68
- Prev close
- 1.68
- Mkt cap
- 96.86M
- Vol
- 320.31K
- Avg vol
- 240.90K
- EPS
- -1.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.65
- High
- 1.78
- Forward P/E
- -1.46
- Beta
- 1.46
- Short ratio
- 4.35
- Inst. own
- 63.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.23
- 200-d avg
- 1.93
- 1y target
- 3.00
6M chart
Signals (30)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Overbought | Oct 2, 2026 | 1 month ago |
| RSI: Overbought | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| RSI: Overbought | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 5, 2026 | 6 months ago |
Key statistics
- Market cap
- 132.67M
- Enterprise value
- -84.89M
- Trailing P/E
- 0.00
- Forward P/E
- -1.46
- PEG ratio
- 0.00
- Price / sales
- 9.08
- Price / book
- 0.39
- EPS (TTM)
- -1.30
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 14.61M
- Revenue growth
- -3.10%
- Free cash flow
- -31.91M
- Total cash
- 247.60M
- Total debt
- 26.50M
- Return on equity
- -22.03%
- Shares outstanding
- 54.92M
- Short % of float
- 2.43%
- 50-day average
- 2.23
- 200-day average
- 1.93
Analyst view
Consensus: none
Price target (mean) 3.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.37372.
Financials — quick view
SEER Revenue — quarterly 3.10M
SEER Net income — quarterly -16.90M
SEER EPS — quarterly -0.31
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.29 | -0.34 | -0.05 | -17.24% |
| Aug 8, 2024 | Jun 1, 2024 | -0.36 | -0.35 | +0.01 | +2.78% |
| Aug 8, 2024 | Jun 1, 2024 | -0.36 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.31 | -0.32 | -0.01 | -3.23% |
| May 8, 2024 | Mar 1, 2024 | -0.31 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.35 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Feb 21, 2023 | Morgan Stanley | main | — | Equal-Weight |
| Jan 4, 2023 | B of A Securities | down | Neutral | Underperform |
| Nov 10, 2022 | Morgan Stanley | main | — | Equal-Weight |
| Aug 11, 2022 | Morgan Stanley | main | — | Equal-Weight |
| Aug 11, 2022 | JP Morgan | down | Overweight | Neutral |
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seer.bio
News
- Seer Announces Its Board Rejects Proposed Acquisition Offers From Bradley L. Radoff And Michael Torok, Omid Farokhzad; Plans To Continue As Independent Entity
- Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process
- Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
- BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
- Seer to Report Third Quarter 2026 Financial Results on November 10, 2026
- Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
- Seer Announces CFO Transition
- Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
- Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.'s Board of Directors
- Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
Your note
Sign in to keep a note on SEER — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FAROKHZAD OMID | Chief Executive Officer | Sale | Mar 6, 2024 | 1,436,280 |
| GULYANI MEETA | Director | Stock Award(Grant) | Jun 11, 2024 | 87,043 |
| HALLAL DAVID L | Director | Stock Award(Grant) | Jun 11, 2024 | 355,128 |
| HAURWITZ RACHEL E. PH.D. | Director | Stock Award(Grant) | Jun 11, 2024 | 87,615 |
| HORN DAVID R. | President | Sale | Feb 21, 2024 | 480,511 |
| KOGAN ELONA | Officer | Sale | Feb 21, 2024 | 273,142 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Softbank Group Corporation | 9.35% | 5,135,383 | 11.55M | Sep 29, 2024 |
| Siren, L.L.C. | 7.28% | 4,000,000 | 9.00M | Sep 29, 2024 |
| Blackrock Inc. | 4.79% | 2,633,090 | 5.92M | Sep 29, 2024 |
| Vanguard Group Inc | 4.27% | 2,343,345 | 5.27M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.19% | 2,300,000 | 5.17M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.94% | 2,165,412 | 4.87M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.90% | 1,594,055 | 3.59M | Sep 29, 2024 |
| Fidelity OTC Portfolio | 1.06% | 584,245 | 1.31M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.94% | 517,365 | 1.16M | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.84% | 462,943 | 1.04M | Sep 29, 2024 |
| BlackRock Advantage Small Cap Core Fund | 0.59% | 322,240 | 725.04K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 239,470 | 538.81K | Oct 30, 2024 |